Other Revenue was Tvardi Therapeutics’s largest product and service line in fiscal 2024, bringing in $4.33M of $7.14M (61%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|
| License & Milestone Fees | $21.22M | $15.00M | $910.00K | — | |||||
| Collaborative Revenue | $706.00K | $16.57M | $12.94M | $2.09M | |||||
| Commercial Supply Revenue | $701.00K | $10.22M | $5.84M | $640.00K | |||||
| Other Revenue | — | — | $699.00K | $4.33M | |||||
| Royalty Revenue | — | $72.00K | $415.00K | — | |||||
| Clinical Compound Revenue | $398.00K | — | $165.00K | $84.00K | |||||
| Total | $23.03M | $41.87M | $20.97M | $7.14M |
Tvardi Therapeutics brought in $7.14M from its four product and service lines in fiscal 2024, the year ended December 31, 2024. Tvardi Therapeutics regrouped these lines after fiscal 2023, so the total does not compare directly with that year's $20.97M. Other Revenue was the largest at $4.33M (60.6%), ahead of Collaborative Revenue at $2.09M (29.2%) and Commercial Supply Revenue at $640.00K (9.0%). The remaining line, Clinical Compound Revenue, brought in $84.00K.
Compared with fiscal 2023, Other Revenue grew fastest, up 519.0% to $4.33M, while Commercial Supply Revenue fell the most, down 89.0% to $640.00K.
Tvardi Therapeutics began breaking out Other Revenue in fiscal 2023, when it brought in $699.00K. Tvardi Therapeutics stopped reporting License & Milestone Fees ($910.00K in fiscal 2023) and Royalty Revenue ($415.00K in fiscal 2023) as separate lines.
Csl Vifor was Tvardi Therapeutics’s largest revenue line in fiscal 2020, bringing in $133.93M of $135.08M (99%).
| Related Party Transaction | FY 2016 | FY 2019 | FY 2020 |
|---|---|---|---|
| Csl Vifor | — | $133.93M | |
| Vifor Fresenius Medical Care Renal Pharma Ltd | $19.75M | — | |
| Chong Kun Dang Pharmaceutical Corp | — | $626.00K | |
| Maruishi Pharmaceutical Co., Ltd | $140.00K | $528.00K | |
| Total | $19.89M | $135.08M |
Tvardi Therapeutics brought in $135.08M from its three revenue lines in fiscal 2020, the year ended December 31, 2020. Tvardi Therapeutics regrouped these revenue lines after fiscal 2019, so the total does not compare directly with that year's $19.89M. Csl Vifor was the largest at $133.93M (99.1%), ahead of Chong Kun Dang Pharmaceutical Corp at $626.00K (0.5%) and Maruishi Pharmaceutical Co., Ltd at $528.00K (0.4%).
Tvardi Therapeutics began breaking out Csl Vifor in fiscal 2020 and Chong Kun Dang Pharmaceutical Corp in fiscal 2020. Tvardi Therapeutics stopped reporting Vifor Fresenius Medical Care Renal Pharma Ltd as a separate revenue line after fiscal 2019, when it brought in $19.75M.
Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 was Tvardi Therapeutics’s largest revenue line in fiscal 2020, bringing in $111.55M of $134.44M (83%).
| Research And Development Arrangement Contract To Perform For Others By Type | FY 2020 |
|---|---|
| Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 | $111.55M |
| Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 | $22.26M |
| Ckdp Agreement | $626.00K |
| Total | $134.44M |
Tvardi Therapeutics brought in $134.44M from its three revenue lines in fiscal 2020, the year ended December 31, 2020. Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 1 was the largest at $111.55M (83.0%), ahead of Vifor Fresenius Medical Care Renal Pharma Ltd Agreement No 2 at $22.26M (16.6%) and Ckdp Agreement at $626.00K (0.5%).
Tvardi Therapeutics (TVRD) reports its revenue by product and service, by related party transaction and by research and development arrangement contract to perform for others by type. In fiscal 2024, Other Revenue was its largest product and service line, bringing in $4.33M (60.6% of the total), followed by Collaborative Revenue at $2.09M (29.2%).
Other Revenue was Tvardi Therapeutics' largest product and service line in fiscal 2024, bringing in $4.33M, or 60.6% of the $7.14M total across its four product and service lines.
Csl Vifor was Tvardi Therapeutics' largest revenue line in fiscal 2020, bringing in $133.93M, or 99.1% of the $135.08M total across its three revenue lines.
Every figure comes from Tvardi Therapeutics' annual financial filings, as reported. Each line keeps the name Tvardi Therapeutics gives it, and years follow its fiscal calendar.
Tvardi Therapeutics' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.